Efficacy, safety and tolerability of CRB-913 in the phase 1b CANYON-1 study
20 November 2026The cannabinoid receptor type 1 (CB1) is a G protein-coupled receptor with a well-established role in obesity and metabolism,
and is abundant in the brain and in peripheral metabolic organs including the liver, pancreas, muscles and adipose tissue. This
insight led to the development of the first-generation CB1 inverse agonists for the treatment of obesity two decades ago.
Download the "Efficacy, safety and tolerability of CRB-913 in the phase 1b CANYON-1 study" poster.